YOUSUF HUSSAIN MOHAMMED

Dr. YOUSUF HUSSAIN MOHAMMED

University of Queensland, Brisbane, Queensland, Australia
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2023 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
NHNazeer Hasan
Nazeer Hasan
ANArif Nadaf
Arif Nadaf
MIMohammad Imran
Mohammad Imran
UJUmme Jiba
Umme Jiba
ASAfsana Sheikh
Afsana Sheikh
FAFarhan Jalees Ahmad
Farhan Jalees Ahmad
Skin cancer is a global threat to the healthcare system and is estimated to incline tremendously in the next 20 years, if not diagnosed at an early stage. Even though it is curable at an early stage, novel drug identification, clinical success, and drug resistance is another major challenge. To bridge the gap and bring effective treatment, it is important to understand the etiology of skin carcinoma, the mechanism of cell proliferation, factors affecting cell growth, and the mechanism of drug resistance. The current article focusses on understanding the structural diversity of skin cancers, treatments available till date including phytocompounds, chemotherapy, radiotherapy, photothermal therapy, surgery, combination therapy, molecular targets associated with cancer growth and metastasis, and special emphasis on nanotechnology-based approaches for downregulating the deleterious disease. A detailed analysis with respect to types of nanoparticles and their scope in overcoming multidrug resistance as well as associated clinical trials has been discussed. Graphical Abstract

29 May 2019 in Current Drug Delivery
Verified
Journal Article
Open access
PDF file
Heather BensonHeather Benson
Heather Benson
JGJeffrey E. Grice
Jeffrey E. Grice
YOUSUF HUSSAIN MOHAMMEDYOUSUF HUSSAIN MOHAMMED
YOUSUF HUSSAIN MOHAMMED
SNSarika Namjoshi
Sarika Namjoshi
Michael RobertsMichael Roberts
Michael Roberts
This overview on skin delivery considers the evolution of the principles of percutaneous absorption and skin products from ancient times to today. Over the ages, it has been recognised that products may be applied to the skin for either local or systemic effects. As our understanding of the anatomy and physiology of the skin has improved, this has facilitated the development of technologies to effectively and quantitatively deliver solutes across this barrier to specific target sites in the skin and beyond. We focus on these technologies and their role in skin delivery today and in the future.

1 October 2016 in Clinical Pharmacology: Advances and Applications
Verified
Journal Article
Open access
PDF file
EAEman Abd
Eman Abd
SYShereen Yousuf
Shereen Yousuf
MPMichael N Pastore
Michael N Pastore
KTKrishna chaitanya Telaprolu
Krishna chaitanya Telaprolu
YOUSUF HUSSAIN MOHAMMEDYOUSUF HUSSAIN MOHAMMED
YOUSUF HUSSAIN MOHAMMED
Michael RobertsMichael Roberts
Michael Roberts
The assessment of percutaneous permeation of molecules is a key step in the evaluation of dermal or transdermal delivery systems. If the drugs are intended for delivery to humans, the most appropriate setting in which to do the assessment is the in vivo human. However, this may not be possible for ethical, practical, or economic reasons, particularly in the early phases of development. It is thus necessary to find alternative methods using accessible and reproducible surrogates for in vivo human skin. A range of models has been developed, including ex vivo human skin, usually obtained from cadavers or plastic surgery patients, ex vivo animal skin, and artificial or reconstructed skin models. Increasingly, largely driven by regulatory authorities and industry, there is a focus on developing standardized techniques and protocols. With this comes the need to demonstrate that the surrogate models produce results that correlate with those from in vivo human studies and that they can be used to show bioequivalence of different topical products. This review discusses the alternative skin models that have been developed as surrogates for normal and diseased skin and examines the concepts of using model systems for in vitro–in vivo correlation and the demonstration of bioequivalence.

1 February 2017 in Journal of Controlled Release
Verified
Journal Article
Closed access
Michael RobertsMichael Roberts
Michael Roberts
YOUSUF HUSSAIN MOHAMMEDYOUSUF HUSSAIN MOHAMMED
YOUSUF HUSSAIN MOHAMMED
MPMn Pastore
Mn Pastore
SNS Namjoshi
S Namjoshi
SYS Yousef
S Yousef
JGJe Grice
Je Grice

1 February 2019 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
YOUSUF HUSSAIN MOHAMMEDYOUSUF HUSSAIN MOHAMMED
YOUSUF HUSSAIN MOHAMMED
AHAmy Holmes
Amy Holmes
IHIsha N. Haridass
Isha N. Haridass
WSWashington Y. Sanchez
Washington Y. Sanchez
HSHauke Studier
Hauke Studier
Michael RobertsMichael Roberts
Michael Roberts

23 March 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SNSarika Namjoshi
Sarika Namjoshi
MDMaryam Dabbaghi
Maryam Dabbaghi
Michael RobertsMichael Roberts
Michael Roberts
JGJeffrey Grice
Jeffrey Grice
YOUSUF HUSSAIN MOHAMMEDYOUSUF HUSSAIN MOHAMMED
YOUSUF HUSSAIN MOHAMMED
In recent years, the “quality by design” (QbD) approach has been used for developing pharmaceutical formulations. This is particularly important for complex dosage forms such as topical semisolid products. The first step for developing a product using this efficient approach is defining the quality target product profile (QTPP), a list of quality attributes (QAs) that are required to be present in the final product. These quality attributes are affected by the ingredients used as well as manufacturing procedure parameters. Hence, critical material attributes (CMAs) and critical process parameters (CPPs) need to be specified. Possible failure modes of a topical semisolid product can be determined based on the physiochemical properties of ingredients and manufacturing procedures. In this review, we have defined and specified QTPP, QAs, CMAs and CPPs that are required for developing a topical semisolid product based on the QbD approach.